MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 310148 | Name: Cisatracurium besylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cisatracurium (formerly recognized as 51W89, and marketed as Nimbex) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.

Chemical Structure

Cisatracurium besylate
Cisatracurium besylate
CAS#96946-42-8 (besylate)

Theoretical Analysis

MedKoo Cat#: 310148

Name: Cisatracurium besylate

CAS#: 96946-42-8 (besylate)

Chemical Formula: C65H82N2O18S2

Exact Mass: 1242.5004

Molecular Weight: 1243.48

Elemental Analysis: C, 62.78; H, 6.65; N, 2.25; O, 23.16; S, 5.16

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 Weeks
100mg USD 400.00 2 Weeks
250mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
64228-81-5 (besylate_mixture of isomers) 96946-41-7 (free base) 96946-42-8 (besylate)
Synonym
51W89 besylate; Cisatracurium besilate; Cisatracurium (besylate); 51W89
IUPAC/Chemical Name
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfonate
InChi Key
XXZSQOVSEBAPGS-DONVQRBFSA-L
InChi Code
InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2/t42-,43-,54-,55-;;/m1../s1
SMILES Code
O=C(OCCCCCOC(CC[N@+]1(C)[C@H](CC2=CC=C(OC)C(OC)=C2)C3=C(C=C(OC)C(OC)=C3)CC1)=O)CC[N@+]4(C)[C@H](CC5=CC=C(OC)C(OC)=C5)C6=C(C=C(OC)C(OC)=C6)CC4.O=S(C7=CC=CC=C7)([O-])=O.O=S(C8=CC=CC=C8)([O-])=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,243.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Strawbridge AD, Khanna NR, Hauser JM. Cisatracurium. 2022 Jul 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30969664. 2: Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guérin C, Prat G, Morange S, Roch A; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372. PMID: 20843245. 3: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Cisatracurium. 2022 Nov 30. PMID: 29999740. 4: National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, Grissom CK, Gundel S, Hayden D, Hite RD, Hou PC, Hough CL, Iwashyna TJ, Khan A, Liu KD, Talmor D, Thompson BT, Ulysse CA, Yealy DM, Angus DC. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019 May 23;380(21):1997-2008. doi: 10.1056/NEJMoa1901686. Epub 2019 May 19. PMID: 31112383; PMCID: PMC6741345. 5: Wen Q, Zhang J, Zhang Z, Chen L, Liu H, Han Z, Chen Y, Wang K, Liu J, Sai N, Zhou X, Zhou C, Hu S, Ma L. Cisatracurium besylate rescues Mycobacterium Tuberculosis-infected macrophages from necroptosis and enhances the bactericidal effect of isoniazid. Int Immunopharmacol. 2023 Jul;120:110291. doi: 10.1016/j.intimp.2023.110291. Epub 2023 May 12. PMID: 37182451. 6: Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017 Aug 14;8(8):CD012763. doi: 10.1002/14651858.CD012763. PMID: 28806470; PMCID: PMC6483345. 7: Xu QA, Zhang YP, Trissel LA, Gilbert DL, Martinez JF, Fox JL. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures. Am J Health Syst Pharm. 1998 May 15;55(10):1037-41. doi: 10.1093/ajhp/55.10.1037. PMID: 9606456. 8: Ortiz JR, Percaz JA, Carrascosa F. Cisatracurio [Cisatracurium]. Rev Esp Anestesiol Reanim. 1998 Jun-Jul;45(6):242-7. Spanish. PMID: 9719722. 9: Trissel LA, Martinez JF, Gilbert DL Jr. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health Syst Pharm. 1997 Aug 1;54(15):1735-41. doi: 10.1093/ajhp/54.15.1735. PMID: 9262747. 10: Jensen FS, Mogensen JV. Cisatracurbesylat--Nimbex [Cisatracurium besylate-- Nimbex]. Ugeskr Laeger. 1998 Feb 2;160(6):858-60. Danish. PMID: 9469987. 11: Wang N, Zhang Y, Hu Y, Yang Q, Su Z. Serious bronchospasm induced by cisatracurium besylate: A case report. Medicine (Baltimore). 2021 Apr 16;100(15):e25516. doi: 10.1097/MD.0000000000025516. PMID: 33847670; PMCID: PMC8051963. 12: Huang S, Li Q. Comparative Analysis of the Anesthesia Effect of Cisatracurium Besylate and Mivacurium Chloride Otolaryngology Surgery. Evid Based Complement Alternat Med. 2022 Jul 18;2022:6192409. doi: 10.1155/2022/6192409. PMID: 35899229; PMCID: PMC9313922. 13: Donati F, Plaud B. Rocuronium-cisatracurium combinations. Anesthesiology. 1999 Aug;91(2):587-8. doi: 10.1097/00000542-199908000-00054. PMID: 10443637. 14: Zhuang H, Tian W, Li W, Zhang X, Wang J, Yang Y, Liu X, Xia Z, Feng D, Zhang L. Autophagic Cell Death and Apoptosis Jointly Mediate Cisatracurium Besylate- Induced Cell Injury. Int J Mol Sci. 2016 Apr 6;17(4):515. doi: 10.3390/ijms17040515. PMID: 27058536; PMCID: PMC4848971. 15: Ingebrigtson M, Farina N, Miller J, Renius K, McSparron JI, Kenes M. Cisatracurium Dosing Requirements in COVID-19 Compared to Non-COVID-19 Patients. J Pharm Pract. 2023 Jun;36(3):485-486. doi: 10.1177/08971900211052835. Epub 2021 Oct 21. PMID: 34674581; PMCID: PMC10189524. 16: Szakmany T, Woodhouse T. Use of cisatracurium in critical care: a review of the literature. Minerva Anestesiol. 2015 Apr;81(4):450-60. Epub 2014 Apr 10. PMID: 24721895. 17: Clar DT, Liu M. Nondepolarizing Neuromuscular Blockers. 2022 Dec 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30521249. 18: do Nascimento FB, Valente Sá LG, de Andrade Neto JB, Cabral VP, Rodrigues DS, Barbosa AD, Moreira LE, Oliveira LC, Silva A, Lima IS, Silva J, Marinho ES, Santos HS, Cavalcanti BC, Morais MO, Júnior HV, Silva CR. Antifungal activity of cisatracurium against fluconazole-resistant Candida isolates and its antibiofilm effects. Future Microbiol. 2023 Jul 31. doi: 10.2217/fmb-2022-0224. Epub ahead of print. PMID: 37522164. 19: Yu DJ, Gao HY. Influences of cisatracurium besylate and vecuronium bromide on muscle relaxant effects and electromyography of tracheal intubation under general anesthesia. Eur Rev Med Pharmacol Sci. 2017 Apr;21(8):1974-1979. PMID: 28485777. 20: Wu LL, Luo H, Lei GY, Lu JF, Chen YM, Hu CH, Chen HY, Wei Z, Xi CH, Wang GY. [Comparison of the anesthetic effects of mivacurium and cisatracurium besylate in laser laryngeal microsurgery]. Zhonghua Yi Xue Za Zhi. 2022 Jun 7;102(21):1574-1578. Chinese. doi: 10.3760/cma.j.cn112137-20220204-00234. PMID: 35644957.

View History

LSN3154567

LSN3154567

New Featured